Literature DB >> 33188512

Current perspectives on the tumor microenvironment in hepatocellular carcinoma.

Cositha Santhakumar1,2, Edward J Gane3, Ken Liu4,5, Geoffrey W McCaughan4,5.   

Abstract

Hepatocellular carcinoma (HCC) is a heterogeneous inflammation-driven malignancy, which, despite significant advances in management, continues to portend a poor prognosis. Recent advances in basic and translational research have increasingly defined the role of the tumor microenvironment in the development and progression of HCC and facilitated the development of novel molecular targets. The hepatoma microenvironment is characterised by an immunosuppressive milieu of immune cells and tumor vasculature that is both structurally and functionally abnormal. Normalising the tumor microenvironment by adopting a multipronged approach that targets both carcinogenic processes and the immunosuppressive milieu has been supported by pre-clinical and clinical data. In this review, we summarise the current understanding of the hepatoma microenvironment, its influences and dynamic interactions with tumor cells, the vasculature and the gut. Finally, we discuss how manipulating the tumor microenvironment continues to shape the evolving landscape of HCC therapy.

Entities:  

Keywords:  Carcinogenesis; Hepatocellular carcinoma; Inflammation; Microbiome; Microenvironment; Prognosis; Single cell sequencing; Vasculature; Vessel normalisation; immunotherapy

Year:  2020        PMID: 33188512     DOI: 10.1007/s12072-020-10104-3

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  13 in total

Review 1.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

Review 2.  Current Strategies for the Treatment of Hepatocellular Carcinoma by Modulating the Tumor Microenvironment via Nano-Delivery Systems: A Review.

Authors:  Yongjie Huang; Tiansi Wang; Jiefen Yang; Xin Wu; Wei Fan; Jianming Chen
Journal:  Int J Nanomedicine       Date:  2022-05-20

Review 3.  The Epigenetic Regulation of Microenvironment in Hepatocellular Carcinoma.

Authors:  Fang Wang; Greg Malnassy; Wei Qiu
Journal:  Front Oncol       Date:  2021-03-15       Impact factor: 6.244

4.  BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.

Authors:  Han Chen; Kouki Nio; Hong Tang; Taro Yamashita; Hikari Okada; Yingyi Li; Phuong Thi Bich Doan; Ru Li; Junyan Lv; Yoshio Sakai; Tatsuya Yamashita; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

5.  Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics.

Authors:  Qijie Zhao; Rawiwan Wongpoomchai; Arpamas Chariyakornkul; Zhangang Xiao; Chalermchai Pilapong
Journal:  Front Oncol       Date:  2021-10-22       Impact factor: 6.244

Review 6.  Drug delivery strategy in hepatocellular carcinoma therapy.

Authors:  Sisi Yang; Chengwei Cai; Huanqiu Wang; Xueqing Ma; Anwen Shao; Jifang Sheng; Chengbo Yu
Journal:  Cell Commun Signal       Date:  2022-03-05       Impact factor: 5.712

7.  Immune-Related lncRNA Pairs Clinical Prognosis Model Construction for Hepatocellular Carcinoma.

Authors:  Yinghui Zhu; Dezhi Shan; Lianyi Guo; Shujia Chen; Xiaofei Li
Journal:  Int J Gen Med       Date:  2022-02-22

Review 8.  Exosomes in Pathogenesis, Diagnosis, and Treatment of Hepatocellular Carcinoma.

Authors:  Shuang Li; Limin Chen
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

9.  Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma.

Authors:  He-Qing Huang; Gang Chen; Dan-Dan Xiong; Ze-Feng Lai; Li-Min Liu; Ye-Ying Fang; Jin-Hai Shen; Xiang-Yu Gan; Liu-Feng Liao; Yi-Wu Dang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 10.  Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.

Authors:  Shahbaz Khan; Romil Saxena
Journal:  Adv Anat Pathol       Date:  2021-11-01       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.